Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mizuho Financial Group Inc. Sponosred ADR (Japan) (MFG) vs TG Therapeutics Inc (TGTX) Price & Performance

Mizuho Financial Group Inc. Sponosred ADR (Japan)Trade
TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Mizuho Financial Group Inc. Sponosred ADR (Japan) vs TG Therapeutics Inc — how do they compare? Mizuho Financial Group Inc. Sponosred ADR (Japan) trades at $10.59 (market cap $127.85B), while TG Therapeutics Inc trades at $54.9 (market cap $8.16B). The key difference: Mizuho Financial Group Inc. Sponosred ADR (Japan) is far larger — about 15.7× TG Therapeutics Inc's market cap, and Mizuho Financial Group Inc. Sponosred ADR (Japan) pays a 1.72% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mizuho Financial Group Inc. Sponosred ADR (Japan) for 1 Days and TG Therapeutics Inc for 16 Days on average.

MFGTGTX
Market Cap
$127.85B$8.16B
Volume
3,950,7501,735,121
Sector
FinancialsHealth
52-Week High
$11.45$59.06
52-Week Low
$6.09$26.94
Typical Hold Time
1 Days16 Days
Enterprise Value
$35.14T$8.37B
Dividend Yield
1.72%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mizuho Financial Group Inc. Sponosred ADR (Japan)

No Aura AI signal available yet.

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.

The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MFG

No sentiment data available yet.

TGTX
0% Buy100% Sell
Avg holding period · 16 Days

About Mizuho Financial Group Inc. Sponosred ADR (Japan)

Mizuho Financial Group is a Japanese financial services company offering banking, trust, securities, and asset management services. It serves retail, corporate, and institutional clients globally.

Read more on MFG →

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX →